Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 10:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: methylprednisolone Clear all
Completed Phase 4 Interventional

Bromfenac BID Plus Prednisolone Acetate BID Versus Bromfenac BID Plus Prednisolone QID for the Prevention of Cystoid Macular Edema and Retinal Thickening

NCT00469781
View directory record Official record
Conditions
Cystoid Macular Edema,, Retinal Thickening
Interventions
2. Xibrom (Bromfenac), 1. Pred Forte
Drug
Lead sponsor
Center For Excellence In Eye Care
Other
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 24, 2008 · Synced Sep 25, 2026, 10:59 PM EDT
Enrolling by invitation Phase 4 Interventional

Quality Improvement and Practice Based Research in Neurology Using the EMR

NCT02670161
View directory record Official record
Conditions
Brain Tumors, Epilepsy, Migraine, Mild Cognitive Impairment, Concussion, Multiple Sclerosis, Neuropathy, Parkinson's, Restless Legs Syndrome, Stroke
Interventions
Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 100 Years
Enrollment
3,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 23, 2025 · Synced Sep 25, 2026, 10:59 PM EDT
Completed Phase 4 Interventional Results available

Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant

NCT04104438
View directory record Official record
Conditions
Asses Immunosuppression Modulation on Renal Recovery Post LT
Interventions
Basiliximab 20 MG
Drug
Lead sponsor
Fady M Kaldas, M.D., F.A.C.S.
Other
Eligibility
18 Years to 78 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Sep 25, 2026, 10:59 PM EDT
Terminated Not applicable Interventional Results available

Dexamethasone Versus Depo Medrol in Lumbar Epidurals

NCT01397552
View directory record Official record
Conditions
Lumbar Spine Disc Herniation, Lumbar Radiculitis, Lumbar Back Pain
Interventions
Dexamethasone, methylprednisolone acetate
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
21 Years to 89 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
East Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Sep 25, 2026, 10:59 PM EDT
Withdrawn Phase 2 Interventional

Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab

NCT01275287
View directory record Official record
Conditions
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Interventions
Standard of care treatment, eculizumab
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Sep 25, 2026, 10:59 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A 3-arm Multi-center, Randomized Controlled Study Comparing Transforaminal Corticosteroid, Transforaminal Etanercept and Transforaminal Saline for Lumbosacral Radiculopathy

NCT00733096
View directory record Official record
Conditions
Lumbosacral Radiculopathy
Interventions
etanercept, methylprednisolone, normal saline
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Fort Bragg, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 7, 2012 · Synced Sep 25, 2026, 10:59 PM EDT
Completed Phase 2 Interventional Results available

Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.

NCT01972217
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Olaparib, Placebo, Abiraterone, Prednisone or prednisolone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Male only
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
2
States / cities
San Diego, California • Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Sep 25, 2026, 10:59 PM EDT
Active, not recruiting Phase 1 Interventional

Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH

NCT04540380
View directory record Official record
Conditions
Renal Failure
Interventions
Rituximab, Fludarabine, Cyclophosphamide, Thymic irradiation and Siplizumab, Combined bone marrow and kidney transplant
Drug · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Sep 25, 2026, 10:59 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Thymus Transplantation With Immunosuppression #950

NCT00579527
View directory record Official record
Conditions
DiGeorge Anomaly, Complete DiGeorge Anomaly, Complete Atypical DiGeorge Anomaly, Complete DiGeorge Syndrome, Complete Atypical DiGeorge Syndrome
Interventions
Cultured Thymus Tissue for Implantation (CTTI), Cultured Thymus Tissue Implantation and Parental Parathyroid Transplantation, Blood Draw, Rabbit anti-thymocyte globulin, Cyclosporine, Tacrolimus, Methylprednisolone or Prednisolone, Daclizumab, Mycophenolate mofetil
Biological · Other · Procedure + 1 more
Lead sponsor
Sumitomo Pharma Switzerland GmbH
Industry
Eligibility
Not listed
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Sep 25, 2026, 10:59 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis

NCT01505088
View directory record Official record
Conditions
Anterior Uveitis
Interventions
40 mg/mL Dexamethasone phosphate ophthalmic solution, Prednisolone Acetate (1%) Eyedrops, 100 mM sodium citrate buffer solution, Placebo Eyedrops
Drug
Lead sponsor
Eyegate Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 85 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
39
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2013 · Synced Sep 25, 2026, 10:59 PM EDT
Not listed Not applicable Interventional

Neuroma Injections to Treat Restless Legs Syndrome - RCT

NCT00656110
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
equal parts of 0.5% plain Marcaine and 2% lidocaine mixed with 0.8 mg Depo-medrol/4% absolute alcohol in a total injection volume of 1 ml, Normal saline - 1ml
Drug
Lead sponsor
Lowcountry Infectious Diseases
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 9, 2009 · Synced Sep 25, 2026, 10:59 PM EDT
Completed Phase 2 Interventional

Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma

NCT00004192
View directory record Official record
Conditions
Lymphoma, Neutropenia
Interventions
filgrastim, pegfilgrastim, cisplatin, cytarabine, etoposide, methylprednisolone
Biological · Drug
Lead sponsor
University of Nebraska
Other
Eligibility
18 Years to 120 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
3
States / cities
Los Angeles, California • Omaha, Nebraska • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Sep 25, 2026, 10:59 PM EDT
Completed Phase 2 Interventional Results available

Immunosuppression in Amyotrophic Lateral Sclerosis (ALS)

NCT01884571
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Basiliximab, Methylprednisolone, Prednisone, Tacrolimus, Mycophenolate mofetil
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Atlanta, Georgia • Boston, Massachusetts • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 25, 2026, 10:59 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas

NCT03586999
View directory record Official record
Conditions
Peripheral T Cell Lymphoma
Interventions
Nivolumab, Etoposide, Prednisolone, Oncovin, Cyclophosphamide, Hydroxydaunorubicin
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Duarte, California • Aurora, Colorado • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Sep 25, 2026, 10:59 PM EDT
Not listed Phase 1Phase 2 Interventional

CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant

NCT02061800
View directory record Official record
Conditions
Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS), Juvenile Myelomonocytic Leukemia (JMML), Acute Lymphoblastic Leukemia (ALL), Lymphoma (Hodgkin's and Non-Hodgkin's)
Interventions
CliniMACS CD34+ Reagent System, Thiotepa, Cyclophosphamide, Alemtuzumab, Tacrolimus, Melphalan, Busulfan, Fludarabine, Methylprednisolone
Device · Drug
Lead sponsor
Diane George
Other
Eligibility
Up to 22 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Sep 25, 2026, 10:59 PM EDT
Completed Phase 3 Interventional

A Sequenced Strategy for Improving Outcomes in People With Knee Osteoarthritis Pain

NCT04504812
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Duloxetine, Intra-Articular Injection, Nerve Procedure with long acting blocks, Nerve Procedure with nerve ablation, Pain Coping Skills Training, Best Practices
Drug · Combination Product · Procedure + 2 more
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
1,937 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
24
States / cities
Sacramento, California • San Diego, California • Aurora, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 25, 2026, 10:59 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL

NCT01897571
View directory record Official record
Conditions
B-cell Lymphomas (Phase 1), Advanced Solid Tumors (Phase 1), Diffuse Large B-cell Lymphoma (Phase 2), Follicular Lymphoma (Phase 2), Transformed Follicular Lymphoma, Primary Mediastinal Large B-Cell Lymphoma
Interventions
Tazemetostat, Prednisolone
Drug
Lead sponsor
Epizyme, Inc.
Industry
Eligibility
16 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
12
States / cities
Birmingham, Alabama • Duarte, California • Santa Barbara, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Sep 25, 2026, 10:59 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

NCT00792948
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Adult L1 Acute Lymphoblastic Leukemia, Adult L2 Acute Lymphoblastic Leukemia, Adult T Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cytarabine, Dasatinib, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Filgrastim, Laboratory Biomarker Analysis, Leucovorin Calcium, Methotrexate, Methylprednisolone, Peripheral Blood Stem Cell Transplantation, Prednisone, Sirolimus, Tacrolimus, Total-Body Irradiation, Vincristine Sulfate
Procedure · Drug · Biological + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 60 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2027
U.S. locations
157
States / cities
Tucson, Arizona • Duarte, California • Palo Alto, California + 114 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 25, 2026, 10:59 PM EDT
Not listed Not applicable Interventional

Longitudinal Optic Neuritis Study (LONS)

NCT00000147
View directory record Official record
Conditions
Multiple Sclerosis, Optic Neuritis
Interventions
Methylprednisolone, Prednisone
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years to 46 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1988
U.S. locations
15
States / cities
Little Rock, Arkansas • San Francisco, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated May 28, 2006 · Synced Sep 25, 2026, 10:59 PM EDT
Completed Phase 2 Interventional Results available

Effectiveness of the Investigational Drug Campath-1H in Preventing Rejection of Transplanted Kidneys

NCT00001984
View directory record Official record
Conditions
Graft Rejection, Kidney Disease
Interventions
Alemtuzumab and DSG
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Sep 25, 2026, 10:59 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Non-Infectious Anterior Uveitis

NCT02517619
View directory record Official record
Conditions
Anterior Uveitis
Interventions
Dexamethasone Phosphate Ophthalmic Solution, Prednisolone Acetate Ophthalmic (1%)
Drug
Lead sponsor
Eyegate Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 85 Years
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Sep 25, 2026, 10:59 PM EDT
Completed Phase 4 Interventional Results available

Dosing Requirements of Astagraf XL® in African American Kidney Transplant Recipients

NCT02953873
View directory record Official record
Conditions
Immunosuppression
Interventions
Tacrolimus Extended Release Capsule, Mycophenolate mofetil, Prednisone, Mycophenolate Sodium
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 25, 2019 · Synced Sep 25, 2026, 10:59 PM EDT
Completed Phase 2 Interventional

Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders

NCT00055653
View directory record Official record
Conditions
Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic-Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, filgrastim, busulfan, cyclophosphamide, cyclosporine, fludarabine phosphate, melphalan, methylprednisolone, umbilical cord blood transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
Up to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
25
States / cities
Duarte, California • Los Angeles, California • Orange, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2011 · Synced Sep 25, 2026, 10:59 PM EDT
Completed Phase 2 Interventional Results available

Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL

NCT00732498
View directory record Official record
Conditions
Lymphoma
Interventions
Methylprednisolone, Etoposide, Cytarabine, Cisplatin, Rituximab, In-Zevalin, Y-Zevalin
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Sep 25, 2026, 10:59 PM EDT